Q-omics provides the consensus-scored PLCH2 profile across patient tissues and cancer cell-line models. PLCH2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, PLCH2 is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, PLCH2 RNA expression shows 18,358 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, KIRP, and GBM as cancer lineages where PLCH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLCH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLCH2 survival associations across molecular data types. PLCH2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLCH2 RNA expression–survival associations across cancer types. High PLCH2 expression shows unfavorable associations in COAD, UVM and THCA, but favorable associations in UCS, KIRP and STAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify COAD as the clearest survival context for PLCH2 RNA expression.
This table summarizes PLCH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PLCH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLCH2 shows lower tumor expression in KIRP, KICH and BRCA and higher tumor expression in LUSC, COAD and HNSC. The KIRP box plot shows higher PLCH2 RNA expression in normal versus tumor tissue (log2 FC = −2.013, t-test p < 0.001).
This table shows molecular features associated with PLCH2 in patient tissues and cancer cell lines. In patient samples, PLCH2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLCH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
